4[1]Jones P,Kafonek S,Laurora I,et al.Com parative dose efficacy study of atorvastatin versus simvastatin,pravastatin,lova statin,and fluvastatin in patients with hypercholesterolemia(The CURVES Study)[ J].Am J Cardiol,1998,81(5):582.
5[2]Keutz EV,Schluter G.Preclinical safety ev aluation of cerivastatin,a novel HMG-CoA reductase inhibitor[J].Am J Cardio l,1998,82(4):11J.
6[3]Chong PH,Seeger JD,Franklin C.Clinically relevant differences between the statins:implications for therapeutic selection [J].Am J Med,2001,111(5):390.
7[4]Rosenson RS,Tangney CC.Antiatherothrombot ic properties of statins[J].JAMA,1998,279(20):1643.
8[5]Meier CR,Schlienger RG,Kraenzlin ME,et al.HMG-CoA reductase inhibitors and the risk of fractures[J].JAMA,2000, 283(24):3205.
9[6]Weber W.Drug firm withdraws statin from t he market[J].Lancet,2001,358(9281):568.
10[7]Bernini F,Poli A,Paoletti R.Safety of HMG -CoA reductase inhibitor,focus on atorvastatin[J].Cardiovascular Drugs and Therapy,2001,15(3):211.
